prostate cancer
Blue Earth announces first UK patient received prostate cancer injection
January 13, 2026Research and Development Blue Earth Therapeutics, Oncology, prostate cancer
Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first UK patient has received its …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
June 20, 2025Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction
May 22, 2025Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy
First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated 20 May 2025. Another Day Pharma Ltd, a company developing innovative …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
September 23, 2024Bayer, Cancer, Oncology, orion, prostate cancer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
Full-Life Technologies’ IND application for prostate cancer cleared by FDA
May 30, 2024Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer
Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …
First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment
November 9, 2023Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer
AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …
Lynparza granted approval to treat prostate cancer in Japan
August 25, 2023Research and Development Merck, Oncology, astra zeneca, prostate cancer
AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …
FDA approved Janssen’s Akeega for prostate cancer treatment
August 14, 2023Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer
The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
FDA approves Pfizer’s HRR mCRPC drug
June 21, 2023Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer
US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
Medical cannabis formulation kills prostate cancer in laboratory tests
July 19, 2021Sales and Marketing medical cannabis, prostate cancer
Apollon Formularies have announced its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate …
New NICE recommendation for Astellas prostate cancer drug
June 8, 2021Manufacturing and Production Astellas, NICE, prostate cancer
A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …
Lucida Medical gains CE marking for AI prostate cancer tech
June 1, 2021Manufacturing and Production AI, MRI, NHS, prostate cancer
Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
